Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study

International Journal of Cardiology

Volumn 188, Issue 1, 2015, Pages 52-53

  Suzuki, Makoto ^a   Fukamizu, Seiji ^b   Oyama, Jun Ichi ^c   Mizukami, Akira ^d   Matsumura, Akihiko ^a   Hashimoto, Yuji ^a   Node, Koichi ^c  

^a KAMEDA MEDICAL CENTER   (Japan)

^b TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d Awa Medical Association Hospital   (Japan)

Author keywords

Atrial fibrillation; Chronic kidney disease; Non Vitamin K antagonist oral anticoagulant; Oral factor Xa inhibitor; Warfarin

Indexed keywords

ALBUMIN; RIVAROXABAN; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; CELL FUNCTION; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRINOLYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; JAPAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON VALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; FOLLOW UP; HEART VALVE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART VALVES; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RIVAROXABAN; TREATMENT OUTCOME; WARFARIN;

EID: 84929305077     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.037     Document Type: Article

References (6)

1. M.R. Patel, Kenneth W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, the ROCKET AF Steering Committee, for the ROCKET AF Investigators, et al., Rivaroxaban versus warfarin in non-valvular atrial fibrillation, N. Engl. J. Med. 365 (2011) 883-891.
2. M. Eto, C. Barandiér, L. Rathgeb, T. Kozai, H. Joch, Z. Yang, T.F. Lüscher, Thrombin suppresses endothelial nitric oxide synthase and up-regulates endothelin-converting enzyme-1 expression by distinct pathways. Role of Rho/ROCK and mitogenactivated protein kinase, Circ. Res. 89 (2001) 583-590.
3. Q. Zhou, F. Bea, M. Preusch, H. Wang, B. Isermann, K. Shahzad, H.A. Katus, E. Blessing, Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban, Mediators Inflamm. 2011 (2011) 9.
4. J.L. Mega, E. Braunwald, S.D. Wiviott, J.-P. Bassand, D.L. Bhatt, C. Bode, P. Burton, M. Cohen, N. Cook-Bruns, K.A.A. Fox, S. Goto, S.A. Murphy, A.N. Plotnikov, D. Schneider, X. Sun, for the ATLAS ACS 2-TIMI 51 Investigators, et al., Rivaroxaban in patients with a recent acute coronary syndrome, N. Engl. J. Med. 366 (2011) 9-19.
5. K.H. Mak, Coronary and mortality risk of novel oral antithrombotic agents: a metaanalysis of large randomized trials, BMJ Open 2 (2012) e001592.
6. T. Inoue, H. Ikeda, T. Nakamura, S. Abe, I. Taguchi, M. Kikuchi, S. Toyoda, M. Miyazono, T. Kishi, T. Sanai, K. Node, Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET), Intern. Med. 50 (2011) 1273-1278.